The 10th PREDiCT: Tumour Models London Summit will return online this December, dedicated to bringing together a community of preclinical and translational scientists with a common goal: narrowing the preclinical gap and progressing efficacious candidates to the clinic.
With the immuno-oncology field constantly evolving and the large breadth of novel therapeutics emerging, it is vital to stay up-to-date on the advances to improve predictability and translatability in models of disease. Delve into how different models are being applied to understand the interactions in the tumour micro-environment, explore resistance mechanisms, effectively translate efficacy, and closer predict in-human effects.
Join us virtually this December to:
-Empower your model toolbox to drive comprehensive and robust data to boost your translational confidence
-Recapitulate the human environment to produce more predictive models, narrow the preclinical gap and guide clinical decisions
-Explore advances in humanised mice, SEMMs, PDX, GEMMs, complex organoids and more
-Deep-dive into the latest approaches for personalised medicine in IO to understand which method suits your study and ultimately provide the best medicine for the patient
-Effectively translate efficacy to drive clinical success and invigorate your pipeline
From early discovery to the early clinic, our packed schedule across 3-days will offer you a comprehensive view of how leading biopharma and expert academics are progressing their IO, targeted and combination therapeutics.
Speakers: Danilo Maddalo Head of Laboratory Roche, Pelin Candarlioglu Cell Biologist & Complex In Vitro Models Bioengineer GlaxoSmithKline, Anita Seshire Head of Laboratory in Exploratory Cancer Research Merck & Co, Barbara Cipriani Head of Biology Pathios Therapeutics, Ann White Senior Principal Scientist UCB Celltech, Thomas Jaquin Principle Scientist & In Vivo Team Leader Pieris, Philip Beer Head of Research & Translational Science Step Pharma, Adam Drake Senior Director In Vivo Pharmacology Ichnos Science, Camilla Rydberg Millrud Project Manager Preclinical Cantargia AB, Jean Viallet Chief Executive Officer Inovotion, Aaron Cranston Head of Translational Research Almac Discovery Ltd, Ludovic Bourre Executive Director, Head of Scientific Engagement Crown Bioscience, Kader Thiam Senior Vice President Discovery – Preclinical Models & Services GenOway, Fallon Noto Executive Director, R&D/In Vivo Oncology Services Hera Biolabs, Holger Weber Head of In Vivo Pharmacology Reaction Biology, Helena Rannikmae Senior Scientist, Complex In Vitro Models GlaxoSmithKline, Chiara Ambrogio Assistant Professor of Molecular Biology University of Turin, Neta Moskovits Head of The Translational Cancer Research Lab Rabin Medical Center, Anna Popova Postdoc & Project Leader Karlsruhe Institute of Technology, Joaquin Arribas Principal Investigator Vall d’Hebron Institute of Oncology, Martin Knight Professor of Mechanobiology Queen Mary University of London, Anna Golebiewska Group Leader NORLUX Neuro- Oncology laboratory Luxembourg Institute of Health, Massimiliano Borsani Research Infrastructure Manager European Institute of Oncology, Geertje van der Horst Senior Scientist Leiden University Medical Center, Ludovic Bigot Project Manager Institut Gustave Roussy, Teresa Marafioti Professor of Haematopathology & Consultant Histopathoogist University College London, Leo Price Senior Vice President, In Vitro Crown Bioscience, Eric Ibsen President Studylog, Senior Representative Labcorp
Time: 9:00 AM - 5:00 PM